Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EPRX NASDAQ:KALA NASDAQ:OGI NASDAQ:TVGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEPRXEupraxia Pharmaceuticals$5.30-1.8%$4.79$2.20▼$6.20$194.18M1.5111,620 shs4,758 shsKALAKALA BIO$7.50+10.8%$5.17$2.92▼$11.20$43.68M-1.81216,393 shs138,258 shsOGIOrganigram Global$1.33-0.7%$1.40$0.85▼$2.08$179.60M1.45582,382 shs721,245 shsTVGNSemper Paratus Acquisition$1.00+1.1%$1.21$0.26▼$3.09$181.93M-0.76591,443 shs380,734 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEPRXEupraxia Pharmaceuticals-1.78%-3.39%-3.03%+32.43%+86.76%KALAKALA BIO+10.78%-7.29%+48.51%+100.00%+13.98%OGIOrganigram Global-0.75%-13.07%-3.62%+15.65%-20.83%TVGNSemper Paratus Acquisition+1.07%-5.67%-20.01%-1.00%+56.23%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEPRXEupraxia Pharmaceuticals2.5642 of 5 stars3.62.00.00.02.60.00.6KALAKALA BIO3.7035 of 5 stars3.52.00.04.41.50.80.6OGIOrganigram Global1.1589 of 5 stars0.02.00.00.02.00.02.5TVGNSemper Paratus Acquisition2.9982 of 5 stars3.53.00.00.00.02.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEPRXEupraxia Pharmaceuticals 3.17Buy$11.00107.39% UpsideKALAKALA BIO 3.00Buy$13.0073.33% UpsideOGIOrganigram Global 0.00N/AN/AN/ATVGNSemper Paratus Acquisition 3.00Buy$10.00900.10% UpsideCurrent Analyst Ratings BreakdownLatest KALA, OGI, EPRX, and TVGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/24/2025EPRXEupraxia PharmaceuticalsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$11.007/11/2025KALAKALA BIOLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.006/26/2025EPRXEupraxia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.006/26/2025EPRXEupraxia PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$12.006/18/2025TVGNSemper Paratus AcquisitionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.006/16/2025EPRXEupraxia PharmaceuticalsCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSpeculative Buy6/10/2025TVGNSemper Paratus AcquisitionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.006/2/2025KALAKALA BIOOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$15.005/27/2025TVGNSemper Paratus AcquisitionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/23/2025KALAKALA BIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $12.005/12/2025TVGNSemper Paratus AcquisitionD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AN/AKALAKALA BIO$3.89M12.44N/AN/A$2.02 per share3.71OGIOrganigram Global$117.47M1.52N/AN/A$2.07 per share0.64TVGNSemper Paratus AcquisitionN/AN/AN/AN/A($0.09) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEPRXEupraxia Pharmaceuticals-$25.50M-$0.76N/AN/AN/AN/A-367.73%-112.23%8/6/2025 (Estimated)KALAKALA BIO-$38.51M-$8.24N/AN/AN/AN/A-369.29%-64.99%8/5/2025 (Estimated)OGIOrganigram Global-$33.39M$0.1013.30N/AN/A8.05%-5.93%-4.39%8/13/2025 (Confirmed)TVGNSemper Paratus Acquisition-$13.73MN/A0.00∞N/AN/AN/A-934.56%8/4/2025 (Estimated)Latest KALA, OGI, EPRX, and TVGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q3 2025OGIOrganigram Global-$0.01N/AN/AN/A$68.04 millionN/A8/6/2025N/AEPRXEupraxia Pharmaceuticals-$0.21N/AN/AN/AN/AN/A8/5/2025Q2 2025KALAKALA BIO-$1.82N/AN/AN/AN/AN/A5/6/2025Q1 2025EPRXEupraxia Pharmaceuticals-$0.19-$0.21-$0.02-$0.21N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEPRXEupraxia PharmaceuticalsN/AN/AN/AN/AN/AKALAKALA BION/AN/AN/AN/AN/AOGIOrganigram GlobalN/AN/AN/AN/AN/ATVGNSemper Paratus AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEPRXEupraxia PharmaceuticalsN/A11.1011.10KALAKALA BIO3.191.991.99OGIOrganigram GlobalN/A3.421.90TVGNSemper Paratus AcquisitionN/A0.350.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEPRXEupraxia PharmaceuticalsN/AKALAKALA BIO24.61%OGIOrganigram Global34.63%TVGNSemper Paratus AcquisitionN/AInsider OwnershipCompanyInsider OwnershipEPRXEupraxia PharmaceuticalsN/AKALAKALA BIO8.32%OGIOrganigram Global0.09%TVGNSemper Paratus Acquisition73.24%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEPRXEupraxia Pharmaceuticals2935.96 millionN/AN/AKALAKALA BIO306.45 million5.92 millionNot OptionableOGIOrganigram Global860134.03 million133.91 millionOptionableTVGNSemper Paratus Acquisition3183.89 million49.21 millionN/AKALA, OGI, EPRX, and TVGN HeadlinesRecent News About These CompaniesTevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to StockholdersAugust 1 at 3:57 PM | globenewswire.comTevogen Bio to Accept $1 Million Additional Grant Funding for AI ExpansionAugust 1 at 3:30 PM | globenewswire.comTevogen Highlights 74% Insider Ownership, Reinforcing Long-Term VisionJuly 30 at 12:41 PM | globenewswire.comTevogen.AI Applauds U.S. Government's AI Action Plan; Reaffirms Commitment to Accelerating AI Innovation in HealthcareJuly 28, 2025 | globenewswire.comSemper Paratus Acquisition (NASDAQ:TVGN) Shares Down 2.7% - Should You Sell?July 24, 2025 | marketbeat.comTevogen.AI Receives International Patent Publication for AI Technology Predicting Immunologically Active PeptidesJuly 18, 2025 | globenewswire.comTevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing FacilityJuly 17, 2025 | globenewswire.comTevogen.AI Targets Faster Time-to-Market with AI-Powered Patient Matching Following PredicTcell™ Alpha LaunchJuly 16, 2025 | globenewswire.comTevogen.AI Builds Alpha Version of PredicTcell™ Model with Microsoft and Databricks; Observes Drastic Time Reduction in Target Analysis Translating to Potential Savings of Billions in Drug Development CostsJuly 14, 2025 | globenewswire.comTevogen's New Headquarters, Fully Funded by CEO, Centralizes R&D and AI Teams to Accelerate InnovationJuly 10, 2025 | globenewswire.comTevogen Bio Holdings Inc News (TVGN) - Investing.comJuly 8, 2025 | investing.comSemper Paratus Acquisition (NASDAQ:TVGN) Shares Down 2.4% - Here's WhyJuly 2, 2025 | marketbeat.comTevogen CEO Contributes to Build-Out and First-Year Operations of New HeadquartersJune 30, 2025 | globenewswire.comTevogen Updates on Development of EBV-Specific T Cell Therapy with Support from AI-Powered Target DiscoveryJune 18, 2025 | globenewswire.comTevogen BioJune 17, 2025 | thepharmaletter.comTTevogen Bio Expands Headquarters To Support Growth In AI And Generics & Biosimilars InitiativesJune 12, 2025 | nasdaq.comTevogen Bio Expands Headquarters to Enhance R&D and Operational Efficiency with Support from MicrosoftJune 10, 2025 | nasdaq.comTevogen Bio doubles Warren HQ footprint for AI expansionJune 10, 2025 | njbiz.comNAmbitious Tevogen makes expansion announcementJune 10, 2025 | thepharmaletter.comTRyan H. Saadi Sells 1,438,206 Shares of Tevogen Bio Holdings Inc. (NASDAQ:TVGN) StockJune 10, 2025 | insidertrades.comTevogen Expands Headquarters Amid Growth of AI and Generics & Biosimilars InitiativesJune 9, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Hot Tech Stocks Showing Bullish Price Action Right NowBy Thomas Hughes | July 11, 2025View 3 Hot Tech Stocks Showing Bullish Price Action Right Now3 Cloud Build-Out Stocks Behind the AI Infrastructure BoomBy Chris Markoch | July 25, 2025View 3 Cloud Build-Out Stocks Behind the AI Infrastructure BoomWhy Lucid’s 36% Rally on Uber Deal Could Be a Game-ChangerBy Leo Miller | July 22, 2025View Why Lucid’s 36% Rally on Uber Deal Could Be a Game-Changer4 Stocks Planning to Substantially Boost Buybacks After Solid Q2By Leo Miller | July 28, 2025View 4 Stocks Planning to Substantially Boost Buybacks After Solid Q2What's Behind Opendoor Technologies' Rally? Is Meme Mania Back?By Gabriel Osorio-Mazilli | July 23, 2025View What's Behind Opendoor Technologies' Rally? Is Meme Mania Back?KALA, OGI, EPRX, and TVGN Company DescriptionsEupraxia Pharmaceuticals NASDAQ:EPRX$5.30 -0.10 (-1.78%) Closing price 08/1/2025 03:50 PM EasternExtended Trading$5.58 +0.27 (+5.18%) As of 08/1/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.KALA BIO NASDAQ:KALA$7.50 +0.73 (+10.78%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$7.60 +0.09 (+1.27%) As of 08/1/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.KALA BIO, Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.Organigram Global NASDAQ:OGI$1.33 -0.01 (-0.75%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.36 +0.03 (+2.56%) As of 08/1/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.Semper Paratus Acquisition NASDAQ:TVGN$1.00 +0.01 (+1.07%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.01 +0.01 (+1.01%) As of 08/1/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale AbbVie Stock Eyes Breakout as Pipeline and Profits Grow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
